IL6 and dilated cardiomyopathy: This is well in line with data reported by D'Onofrio et al., who demonstrated the improvement of inflammatory circulating biomarkers and markers of fibrosis such as collagen 3, collagen 4, C-cystatin and IL-6 after 6 and 12 months of CCM therapy in patient with LMNA-associated dilated cardiomyopathy (13).